The clinical trials of the world's first coronavirus vaccine on volunteers at Sechenov First Moscow State Medical University has been successfully completed, Vadim Tarasov, the director of the Institute for Translational Medicine and Biotechnology, according to Russian news agency Sputnik, adding that the first group of volunteers would be discharged on 15 July and the second on 20 July.
The university began clinical trials of the vaccine produced by Russia's Gamalei Institute of Epidemiology and Microbiology on June 18. In a human challenge trial, participants are deliberately exposed to the infection (in this case it is SARS-CoV-2 virus), in order to study the disease and test the vaccines. For the human challenge trial -- the exact virus strain that is used to infect the participant and dosage or how much of the virus the volunteers need to be exposed to needs to be determined and approved by the regulatory authorities. The method is not new and has been used for developing vaccines for seasonal flu, typhoid, malaria and cholera, among others.